Activated CD4<sup>+</sup> T Cell Proportion in the Peripheral Blood Correlates with the Duration of Cytokine Release Syndrome and Predicts Clinical Outcome after Chimeric Antigen Receptor T Cell Therapy-Reference-Cited by-同舟云学术

Activated CD4<sup>+</sup> T Cell Proportion in the Peripheral Blood Correlates with the Duration of Cytokine Release Syndrome and Predicts Clinical Outcome after Chimeric Antigen Receptor T Cell Therapy

Published:2024-07-01 Issue:13 Volume:63 Page:1863-1872
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Kitamura Wataru¹,Asada Noboru¹,Ikegawa Shuntaro¹²,Fujiwara Hideaki¹,Kamoi Chihiro¹²,Ennishi Daisuke³,Nishimori Hisakazu¹,Fujii Keiko⁴,Fujii Nobuharu²,Matsuoka Ken-ichi¹,Maeda Yoshinobu¹

Affiliation:

1. Department of Hematology and Oncology, Okayama University Hospital, Japan

2. Division of Blood Transfusion, Okayama University Hospital, Japan

3. Center for Comprehensive Genomic Medicine, Okayama University Hospital, Japan

4. Division of Clinical Laboratory, Okayama University Hospital, Japan

Publisher

Japanese Society of Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/63/13/63_2556-23/_pdf

Reference50 articles.

1. 1. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380: 45-56, 2019.

2. 2. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377: 2531-2544, 2017.

3. 3. Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396: 839-852, 2020.

4. 4. Schubert ML, Schmitt M, Wang L, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol 32: 34-48, 2021.

5. 5. Varadarajan I, Lee DW. Management of T-cell engaging immunotherapy complications. Cancer J 25: 223-230, 2019.